NCT00202891 is a Phase 4 clinical trial of sisomicin in Pyoderma, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT00202891?

NCT00202891 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00202891?

Interventions in NCT00202891: sisomicin.

Is NCT00202891 still recruiting?

NCT00202891 is currently withdrawn. Last updated 2 June 2015.

Last reviewed 2015-06-02 · How we verify

NCT00202891

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas

Withdrawn Phase 4 Last updated 2 June 2015

What this trial tests

Phase 4 trial testing sisomicin in Pyoderma. Withdrawn.

Timeline

1 May 2007

1 September 2007

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 May 2007
Estimated completion	1 September 2007

Drugs / interventions tested

sisomicin — full drug profile →

Conditions studied

Pyoderma — all drugs for Pyoderma →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

6 and older, any sex, with Pyoderma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This open-label, randomized, parallel-group clinical study is designed to compare the efficacy and safety of the topical antibiotic, sisomicin cream, with that of another topical antibiotic cream, nadifloxacin cream, in the treatment of Indian patients with primary pyodermas.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for impetigo.
Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, et al · · 2012 · cited 59× · PMID 22258953 · DOI 10.1002/14651858.cd003261.pub3

Verify or expand the search:

Other recruiting trials for Pyoderma

Currently open trials in the same condition.

NCT06563323 — Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) · Phase 2 · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00202891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 2 June 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00202891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing